Dublin, Feb. 03, 2020 (GLOBE NEWSWIRE) -- The "Adult T-Cell Leukemia-Lymphoma - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Adult T-Cell Leukemia-Lymphoma Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the adult t-cell leukemia-lymphoma market. A detailed picture of the adult t-cell leukemia-lymphoma pipeline landscape is provided, which includes the disease overview and adult t-cell leukemia-lymphoma treatment guidelines.

The assessment part of the report embraces in-depth adult t-cell leukemia-lymphoma commercial assessment and clinical assessment of the adult t-cell leukemia-lymphoma pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, adult t-cell leukemia-lymphoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

• All of the companies that are developing therapies for the treatment of adult t-cell leukemia-lymphoma with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the adult t-cell leukemia-lymphoma treatment.
• Adult t-cell leukemia-lymphoma key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of adult t-cell leukemia-lymphoma market.

Scope of the Report

• The adult t-cell leukemia-lymphoma report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and moa type for adult t-cell leukemia-lymphoma across the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of adult t-cell leukemia-lymphoma therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
• detailed adult t-cell leukemia-lymphoma research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across adult t-cell leukemia-lymphoma.

Key Topics Covered

1. Report Introduction

2. Adult T-Cell Leukemia-Lymphoma
2.1. Overview
2.2. History
2.3. Adult T-Cell Leukemia-Lymphoma Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Adult T-Cell Leukemia-Lymphoma Diagnosis
2.6.1. Diagnostic Guidelines

3. Adult T-Cell Leukemia-Lymphoma Current Treatment Patterns
3.1. Adult T-Cell Leukemia-Lymphoma Treatment Guidelines

4. Adult T-Cell Leukemia-Lymphoma - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Adult T-Cell Leukemia-Lymphoma companies collaborations, Licensing, Acquisition - Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Adult T-Cell Leukemia-Lymphoma Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Adult T-Cell Leukemia-Lymphoma Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MoA
5.1.5.1. Assessment by Stage and MoA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Adult T-Cell Leukemia-Lymphoma Late Stage Products (Phase-III)

7. Adult T-Cell Leukemia-Lymphoma Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Adult T-Cell Leukemia-Lymphoma Discontinued Products

13. Adult T-Cell Leukemia-Lymphoma Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table

14. Adult T-Cell Leukemia-Lymphoma Key Companies

15. Adult T-Cell Leukemia-Lymphoma Key Products

16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation

17. Adult T-Cell Leukemia-Lymphoma Unmet Needs

18. Adult T-Cell Leukemia-Lymphoma Future Perspectives

19. Adult T-Cell Leukemia-Lymphoma Analyst Review

20. Appendix

Companies Mentioned

• Daiichi Sankyo Co. Ltd.
• Seattle Genetics Inc.
• miRagen Therapeutics Inc.
• Celgene Corporation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/c31e14

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.